Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018
Summary
SAN DIEGO--( BUSINESS WIRE )--Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2018. “From the evolving regulatory environment for oncology diagnostics to progress in reimbursement for non-invasive prenatal and undiagnosed disease testing, genomics is accelerating on its path into clinical standard of care.” Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance. Fiscal Year 2019GAAP diluted earnings per share attributable to Illumina stockholders (a)$6.07 - $6.17 Amortization of acquired intangible assets 0.24 Non-cash interest expense (b) 0.33 Incremental non-GAAP tax expense (c) (0.14) Non-GAAP diluted earnings per share attributable to Illumina stockholders (a) $6.50 - $6.60 (a) Guidance does not include the potential impact of the pending Pacific Biosciences acquisition, which is expected to close in mid-2019.
Classifications
AskAI Classifications
LabelsLinked Companies
